Vibostolimab/Pembrolizumab clinical trials

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

This study is looking at new combinations of medicines for kidney cancer (renal cell carcinoma) that has spread or come back. We want to see how safe and effective these new treatments are. It's an early-stage study to find the best way to use these combinations.